CDK9/10/GSK3β-IN-1 is a kinase inhibitor with potent anticancer activity, exhibiting strong antiproliferative effects against up to seven cancer cell lines in vitro; it effectively inhibits HsGSK3β (IC50 = 59 nM), HsCDK9/CyclinT (IC50 = 64 nM), HsCDK5/p25 (IC50 = 1.093 µM), and HsCDK2/CyclinA (IC50 = 1.725 µM), demonstrating comparable or superior anticancer cell activity to Flavopiridol.